[关键词]
[摘要]
目的 观察卡马西平联合宁痫丹治疗癫痫的临床疗效及安全性。方法 将42例癫痫患者随机分为治疗组和对照组。对照组服用卡马西平,13岁儿童~成人0.2 g/次,3次/d,6~12岁儿童10~20 mg/(kg?d?1),分3次服用;治疗组服用卡马西平的用法及用量同对照组,另外治疗组患者口服宁痫丹,6岁患儿3 丸/d,7~10岁4~6丸/d,10~14岁6~9丸/d,15岁~成人9~l2丸/d,分3次服用。两组均持续治疗3个月。治疗结束后,观察两组患者临床疗效、癫痫发作次数、治疗前后脑电图异常情况。结果 两组治疗后癫痫发作次数、脑电图异常与治疗前比较差异均有统计学意义(P<0.05),治疗组和对照组总有效率分别为95.24%、66.67%,两组比较差异有统计学意义(P<0.05)。结论 卡马西平联合宁痫丹治疗癫痫可减少患者癫痫发作次数,且不良反应较少,值得临床推广。
[Key word]
[Abstract]
Objective To evaluate the clinical efficiency and security of carbamazepine combined with Ningxian Powder in the treatment of epilepsy. Methods The patients (42 cases) diagnosed as epilepsy were randomly divided into treatment (21 cases) and control (21 cases) groups. The patients in the control group were po administered with carbamazepine, from 13-years old to adult 0.2 g/time and 6—12-years old 10—20 mg/(kg?d?1), for three times daily. The usage and dosage of carbamazepine in the two groups were the same. The patients in the treatment group were po administered with Ningxian Powder, 6-years old children 3 pills/d, 7—10-years old 4—6 pills/d, 10—14-years old 6—9 pills/d, and from 15-years old to adult 9—l2 pills/d for 3-4 doses, daily. The patients in the two groups were treated for three months. At the end of the treatment, the therapeutic effects, numbers of seizures, and EEG abnormalities before and after treatment were observed. Results After the treatment, the numbers of seizures and EEG abnormalities in the two groups were significantly different compared with those before the treatments (P < 0.05). The efficiency of the treatment and control groups was 95.24% and 66.67% with the significant difference (P < 0.05). Conclusion Carbamazepine combined with Ningxian Powder could reduce the numbers of seizures with fewer adverse reactions, which is worthy of promotion.
[中图分类号]
[基金项目]